S. 229 119th Congress Senate

DTC Act of 2025

Official title: A bill to amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an… Show full official titleShow less

Introduced: January 23, 2025 Introduced by: Richard J. Durbin Democratic · Illinois See on congress.gov

Health Administrative law and regulatory proceduresCivil actions and liabilityDepartment of Health and Human ServicesHealth care costs and insurance

More subjectsShow fewer subjects

Marketing and advertisingPrescription drugs

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Jan 23, 2025

Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)

Jan 23, 2025

Introduced in Senate

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now January 23, 2025

Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)

Plain-English summary Congressional Research Service

Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025

This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.

Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.

The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.

Each violation of this requirement is subject to a civil penalty of not more than $100,000.

Related & companion bills 1

Bill text 1 version

Introduced in Senate Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Finance Committee
Senate

Lobbying activity 39

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
for AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
MEHLMAN CONSULTING, INC.
for THE CAMPAIGN FOR SUSTAINABLE RX PRICING · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
AMERICAN ACADEMY OF FAMILY PHYSICIANS
for AMERICAN ACADEMY OF FAMILY PHYSICIANS · Kansas · 3rd Quarter 2026 (July 1 - Sep 30)
COALITION FOR HEALTHCARE COMMUNICATIONS
for COALITION FOR HEALTHCARE COMMUNICATIONS · New York · 3rd Quarter 2026 (July 1 - Sep 30)
WHITMER & WORRALL, LLC
for CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · District of Columbia · 2nd Quarter 2026 (Apr 1 - June 30)
AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
for AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · District of Columbia · 2nd Quarter 2026 (Apr 1 - June 30)

Bodies those filers lobbied

SENATE
37 filings
HOUSE OF REPRESENTATIVES
33 filings
Centers For Medicare and Medicaid Services (CMS)
26 filings
Health & Human Services, Dept of (HHS)
26 filings
White House Office
11 filings
Labor, Dept of (DOL)
9 filings
Executive Office of the President (EOP)
4 filings
Food & Drug Administration (FDA)
4 filings

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 39 filings →

Cosponsors 9